This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: heart failure with reduced ejection fraction

October 2019 Br J Cardiol 2019;26(4) doi:10.5837/bjc.2019.035 Online First

Clinical CMR: one-year case mix, outcomes and stress-testing accuracy from a regional tertiary centre

Protik Chaudhury, Min Aung, Rossella Barbagallo, Edward Barden, Swamy Gedela, Stuart J Harris, Henry O Savage, Jason N Dungu

Abstract

Introduction Cardiac magnetic resonance (CMR) imaging has developed into a crucial diagnostic tool in all patients with known or suspected heart disease. The role of CMR in differentiating ischaemic from non-ischaemic heart disease is well established and there are extensive data in the literature correlating myocardial fibrosis, as identified by the late gadolinium hyperenhancement technique, with adverse outcomes in patients with cardiomyopathy.1 A regional CMR service for the Essex region in southeast England was established in 2012, serving a population of 1,393,587 (2011 census data) with the benefit of avoiding transfer of patients to L

| Full text
Early clinical experience with sacubitril/valsartan from a large UK tertiary centre

July 2019 Br J Cardiol 2019;26(suppl 1):S9-S14 doi:10.5837/bjc.2019.s03

Early clinical experience with sacubitril/valsartan from a large UK tertiary centre

Danish Ali, Jacqui Hyland, Fiona Riley, Stephanie Kirkland, Lisa Hinnit, Sarah Albarad, Rajen Parekh, Catherine Watson, Hayley Nicholson, Johanna McCann, Victoria Allport, Fraz Umar, Prithwish Banerjee

Abstract

Introduction Much progress has been made over the last 30 years in the discovery of evidence-based pharmacological treatments that improve morbidity and mortality in people with heart failure with reduced left ventricular ejection fraction (HFrEF). Landmark trials first established angiotensin-converting enzyme (ACE) inhibitors as the mainstay therapy for heart failure (HF),1-3 with angiotensin II receptor blockers (ARB) subsequently demonstrating similar benefits for patients intolerant to ACE inhibitors.4 Further trials reported improved outcomes with mineralocorticoid receptor antagonists (MRA) used together with ACE inhibitors in HFrEF.5

| Full text
Initial experience of introducing sacubitril/valsartan in a UK heart failure service

July 2019 Br J Cardiol 2019;26(suppl 1):S15-S19 doi:10.5837/bjc.2019.s04

Initial experience of introducing sacubitril/valsartan in a UK heart failure service

Richard J Crawley, Geraint Morton, Navneet Kalsi, Paul R Kalra, Kaushik Guha

Abstract

Introduction Heart failure (HF) remains a significant problem globally.1 In the UK, the prevalence is estimated at over 500,000 individuals,2 with care representing 2% of National Health Service (NHS) resources (approximately £2.3 billion).3 A large proportion of the economic burden relates to lengthy and recurrent hospitalisations. Despite advancements, HF is still associated with a poor prognosis. The National Heart Failure Audit from England and Wales demonstrates an in-hospital mortality rate of around 9%, and a one-year mortality of just over 23%.4 Treatment for patients suffering from HF with reduced ejection fraction (HFrEF) is primar

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now